Changing trends of acute otitis media bacteriology in central Israel in the pneumococcal conjugate vaccines era

Journal of Pediatric Infectious Diseases

Volumn 34, Issue 2, 2015, Pages 195-199

  Tamir, Sharon Ovnat ^a   Roth, Yehudah ^a   Dalal, Ilan ^a   Goldfarb, Abraham ^a   Grotto, Itamar ^b,c   Marom, Tal ^a  

^a WOLFSON MEDICAL CENTER   (Israel)

^b MINISTRY OF HEALTH   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Acute otitis media; Middle ear fluid; Pneumococcal conjugate vaccine; Streptococcus pneumoniae; Tympanocentesis

Indexed keywords

AMOXICILLIN; PNEUMOCOCCUS VACCINE; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; PREVENAR13;

ACUTE OTITIS MEDIA; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL VIRULENCE; BACTERIOLOGY; CHILD; CHILDHOOD DISEASE; DEMOGRAPHY; DRUG EFFECT; FACIAL NERVE PARALYSIS; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; IMMUNIZATION; INFECTION; INTRACRANIAL INFECTION; ISRAEL; MAJOR CLINICAL STUDY; MALE; MASTOIDECTOMY; MASTOIDITIS; MORAXELLA CATARRHALIS; MYRINGOTOMY; OTORRHEA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPSIS; STREPTOCOCCUS PNEUMONIAE; UPPER RESPIRATORY TRACT INFECTION; BACTERIUM; CLASSIFICATION; IMMUNOLOGY; INFANT; ISOLATION AND PURIFICATION; MICROBIOLOGY; OTITIS MEDIA; PRESCHOOL CHILD;

BACTERIA; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; ISRAEL; MALE; OTITIS MEDIA; PNEUMOCOCCAL VACCINES; RETROSPECTIVE STUDIES;

EID: 84925602535     PISSN: 13057707     EISSN: 13057693     Source Type: Journal    
DOI: 10.1097/INF.0000000000000536     Document Type: Article

References (27)

1. Fitzwater SP, Chandran A, Santosham M, et al. The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2012;31:501-508.
2. American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23). Pediatrics. 2010;126(1):186-190.
3. Revai K, McCormick DP, Patel J, et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal bacterial colonization during acute otitis media. Pediatrics. 2006;117:1823-1829.
4. Casey JR, Adlowitz DG, Pichichero ME. New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2010;29:304-309.
5. Cohen R, Bingen E, Levy C, et al. Nasopharyngeal flora in children with acute otitis media before and after implementation of 7 valent pneumococcal conjugate vaccine in France. BMC Infect Dis. 2012;12:52.
6. th Informational Supplement (June 2010 Update). Wayne, PA:CLSI; 2010.
7. Tamir SO, Roth Y, Dalal I, et al. Acute mastoiditis in the pneumococcal conjugate vaccine era. Clin Vaccine Immunol. 2014;21:1189-1191.
8. Zhou F, Shefer A, Kong Y, et al. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004. Pediatrics. 2008;121:253-260.
9. Stamboulidis K, Chatzaki D, Poulakou G, et al. The impact of the heptavalent pneumococcal conjugate vaccine on the epidemiology of acute otitis media complicated by otorrhea. Pediatr Infect Dis J. 2011;30:551-555.
10. Grijalva CG, Poehling KA, Nuorti JP, et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics. 2006;118:865-873.
11. Simell B, Auranen K, Käyhty H, et al Pneumococcal Carriage Group. The fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines. 2012;11:841-855.
12. Weil-Olivier C, van der Linden M, de Schutter I, et al. Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective. BMC Infect Dis. 2012;12:207.
13. Casey JR, Pichichero ME. Changes in frequency and pathogens causing acute otitis media in 1995-2003. Pediatr Infect Dis J. 2004;23:824-828.
14. Cohen R, Levy C, Bingen E, et al. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J. 2012;31:297-301.
15. Lee GM, Kleinman K, Pelton SI, et al. Impact of 13-valent pneumococcal conjugate vaccination on Streptococcus pneumoniae carriage in young children in Massachusetts. J Pediatric Infect Dis Soc. 2014;3:23-32.
16. Zuccotti G, Mameli C, Daprai L, et al; PneuMi Study Group (PMSG). Serotype distribution and antimicrobial susceptibilities of nasopharyngeal isolates of Streptococcus pneumoniae from healthy children in the 13-valent pneumococcal conjugate vaccine era. Vaccine. 2014;32:527-534.
17. Dagan R, Patterson S, Juergens C, et al. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clin Infect Dis. 2013;57:952-962.
18. Ruohola A, Pettigrew MM, Lindholm L, et al. Bacterial and viral interactions within the nasopharynx contribute to the risk of acute otitis media. J Infect. 2013;66:247-254.
19. Cohen R, Levy C, de La Rocque F, et al. Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media. Pediatr Infect Dis J. 2006;25:1001-1007.
20. van Dongen TM, van der Heijden GJ, van Zon A, et al. Evaluation of concordance between the microorganisms detected in the nasopharynx and middle ear of children with otitis media. Pediatr Infect Dis J. 2013;32:549-552.
21. Somech I, Dagan R, Givon-Lavi N, et al. Distribution, dynamics and antibiotic resistance patterns of Streptococcus pneumoniae serotypes causing acute otitis media in children in southern Israel during the 10 year-period before the introduction of the 7-valent pneumococcal conjugate vaccine. Vaccine. 2011;29:4202-4209.
22. Ben-Shimol S, Greenberg D, Givon-Lavi N, et al. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance. Vaccine. 2014;32:3452-3459.
23. Liu K, Kaur R, Almudevar A, et al. Higher serum levels of interleukin 10 occur at onset of acute otitis media caused by Streptococcus pneumoniae compared to Haemophilus influenzae and Moraxella catarrhalis. Laryngoscope. 2013;123:1500-1505.
24. Dagan R, Leibovitz E, Greenberg D, et al. Mixed pneumococcal-nontypeable Haemophilus influenzae otitis media is a distinct clinical entity with unique epidemiologic characteristics and pneumococcal serotype distribution. J Infect Dis. 2013;208:1152-1160.
25. Casey JR, Kaur R, Friedel VC, et al. Acute otitis media otopathogens during 2008 to 2010 in Rochester, New York. Pediatr Infect Dis J. 2013;32:805-809.
26. Setchanova LP, Kostyanev T, Alexandrova AB, et al. Microbiological characterization of Streptococcus pneumoniae and non-typeable Haemophilus influenzae isolates as primary causes of acute otitis media in Bulgarian children before the introduction of conjugate vaccines. Ann Clin Microbiol Antimicrob. 2013;12:6.
27. Magnus MC, Vestrheim DF, Nystad W, et al. Decline in early childhood respiratory tract infections in the Norwegian mother and child cohort study after introduction of pneumococcal conjugate vaccination. Pediatr Infect Dis J. 2012;31:951-955.